Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone hexacetonide
Drug ID BADD_D02274
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Prescription
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00985
MeSH ID C005900
PubChem ID 21826
TTD Drug ID Not Available
NDC Product Code 52128-177; 46439-8728; 59137-570
Synonyms triamcinolone hexacetonide | 9-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-(3,3-dimethylbutyrate) | Aristospan
Chemical Information
Molecular Formula C30H41FO7
CAS Registry Number 5611-51-8
SMILES CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)COC(=O)CC(C)(C)C)C)O)F)C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin hypopigmentation23.05.02.003--
Skin striae23.01.05.002--Not Available
Small intestinal perforation07.04.06.006--
Sodium retention14.05.04.003--Not Available
Spermatozoa abnormal13.20.01.005--Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.001--Not Available
Spinal fracture15.08.05.001; 12.04.04.002--
Syncope17.02.04.008; 02.01.02.008; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Thrombophlebitis24.01.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis24.05.02.001; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
Weight increased13.15.01.006--
Oesophagitis ulcerative07.04.05.003--Not Available
Growth retardation15.03.01.006--
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Congestive cardiomyopathy02.04.01.003--Not Available
Muscle mass15.05.03.018--Not Available
Post procedural complication12.02.05.018--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Embolism24.01.01.009--
Mental disorder19.07.01.002--Not Available
Immediate post-injection reaction10.01.03.032; 08.06.01.019--Not Available
Nail atrophy23.02.05.010--Not Available
Bladder dysfunction20.03.03.002--Not Available
Functional gastrointestinal disorder07.11.01.016--Not Available
The 4th Page    First    Pre   4    Total 4 Pages